{"disease":{"id":"allogeneic-transplantation","name":"allogeneic transplantation"},"drugs":{"marketed":[{"drug_id":"busilvex","indication_name":"Allogeneic bone marrow transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfan","indication_name":"Allogeneic bone marrow transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"busulfex","indication_name":"Allogeneic bone marrow transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Allogeneic bone marrow transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06708130","title":"Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04469985","title":"Allogeneic Stem Cell Transplantation (ALLO-SCT) in Elderly: 17-years Retrospective GITMO Survey","phase":"","overall_status":"COMPLETED","enrollment_count":2061,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT06450353","title":"Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03357172","title":"Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT07463651","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06673459","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":430,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05579639","title":"Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":419,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT07157670","title":"Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07286461","title":"VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":290,"lead_sponsor_name":"University of Rome Tor Vergata","has_results":false},{"nct_id":"NCT04713956","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":242,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT02744742","title":"G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03467074","title":"Role of Interferon-λ and Vaccine Response","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT07101588","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05674539","title":"Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05149365","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07396480","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT06912347","title":"Acupoint Application With Herbal Fumigation and Wash for Preventing Diarrhea-induced Perianal Infection in Allo-HSCT Patients","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":180,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06946654","title":"Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":176,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07289087","title":"Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":162,"lead_sponsor_name":"Associazione Qol-one","has_results":false},{"nct_id":"NCT03902041","title":"The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT07013370","title":"Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Antonello Di Paolo, M.D., Ph.D.","has_results":false},{"nct_id":"NCT05379569","title":"Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":142,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07304232","title":"Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03605953","title":"Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":134,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03148197","title":"Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT03384225","title":"CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04247945","title":"Co-transplantation of MSC in the Setting of Allo-HSCT","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03384212","title":"CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07341698","title":"Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03964922","title":"Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":104,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03678493","title":"A Study of FMT in Patients With AML Allo HSCT in Recipients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT06793410","title":"Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT06936566","title":"MAGIC Ruxolitinib for aGVHD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"John Levine","has_results":false},{"nct_id":"NCT05088941","title":"Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience","phase":"","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04801563","title":"Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT05727917","title":"Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05612789","title":"Improve Outcomes for Older Allogeneic Transplant Recipients","phase":"NA","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT05823714","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02083250","title":"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03779854","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02250300","title":"MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Mehdi Hamadani","has_results":true},{"nct_id":"NCT03719092","title":"High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04995653","title":"A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Seres Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03530085","title":"Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07181330","title":"Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ting YANG","has_results":false},{"nct_id":"NCT05596981","title":"The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05601895","title":"The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05501756","title":"Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT06686108","title":"Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":59,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT02194868","title":"Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}